

## Curriculum vitae

***MUAYAD AGHALI MERZA (MD)***  
***Professor of Infectious Disease***  
**Clinician and Researcher**

**Name:** Muayad Aghali Merza

**Date & Place of Birth:** 2<sup>nd</sup> March 1974, Baghdad-Iraq

**Address:** House: C13, Avrocity - Duhok,  
Kurdistan-Iraq Tel. 062 7615949  
Mobile: 00964 750 450 6172  
[muayad.merza@uod.ac](mailto:muayad.merza@uod.ac)  
[muayad\\_us@hotmail.com](mailto:muayad_us@hotmail.com)



**Nationality:** Iraqi-Kurd

**Gender:** Male

**Marital Status:** Married

## **Educational background:**

**Primary Education**      1980-1986 **Qonatare** primary school – Baghdad –Iraq

**Secondary Education**    1987-1992 **Shahid Sader** secondary school – Tehran - Iran

**University degree**      1993-1999    MBChB, Uni. of **Duhok**/College of Medicine,  
Duhok

### **Higher education**

**(Qualifications)**      2004-2005 MSc, Uni. of **Nottingham**/Faculty of  
Medicine and Health Sciences – Nottingham – UK.

2007- 2011 PhD, University of Duhok in collaboration  
with Shahid Beheshti University of Medical Sciences,  
National Research Institute of Tuberculosis and Lung  
Disease (NRITLD)-Tehran-Iran.

2013-2015 Subspecialty Fellowship in Infectious  
Diseases/Faculty of Medical Sciences, University of  
Duhok in collaboration with Labbafinajad Medical  
Complex, Shahid Beheshti University/Tehran/Iran.

Feb 2020 Fellow of the Royal College of Physicians (of  
Glasgow), FRCP(Glasg) "PID: 143237".

**MSc Thesis:** Management of Postpneumonic Empyema in Children: a 10 Year  
Experience.

**PhD Thesis:** Clinical and Molecular characterization of *Mycobacterium  
tuberculosis* strains isolated from patients in Duhok province,  
Iraqi Kurdistan.

### **Subspecialty**

**Dissertation:** Seroclearance of HBsAg in chronic hepatitis B virus  
patients on lamivudine therapy: a 10-year retrospective  
study

**Areas of Expertise:**

|   |                             |
|---|-----------------------------|
| Infectious Diseases                             | <b>Professional</b>         |
| Clinical Microbiology and clinical Tuberculosis | <b>Professional</b>         |
| General Surgery                                 | <b>General Practitioner</b> |
| Internal Medicine                               | <b>General Practitioner</b> |
| Medical administration                          | <b>Practitioner</b>         |
| Emergency Health programs                       | <b>Practitioner</b>         |
| Public health and staff support                 | <b>Practitioner</b>         |

**Languages spoken:**

- Kurdish (Mother tongue)
- Arabic
- English
- Persian

**Computer literacy:** Windows, Words, Excel, Access, Endnote, Powerpoint and Internet.

**Medical Societies:**

- Member of Iraqi Kurdistan Medical Association (Syndicate) Membership Registration # 1090 dated 13<sup>th</sup> February 2000.
- Fellows of the Royal College of Physicians Glasgow, FRCP(Glasg). Personal ID (PID): 143237.

## **National and International participation's, workshops and trainings:**

- 10-12<sup>th</sup> Dec 2001** Duhok, Kurdistan, **IRAQ**, A workshop on Health Management. Organized by Dr. Enayatulla Aman, UNWHO officer in charge – Duhok sub-office.
- 28-31<sup>st</sup> Dec 2002** Duhok, Kurdistan, **IRAQ**, First workshop on communicable Diseases control in Complex Emergency Situation. Organized by Dr. Chehrezad Ghazi, UNWHO acting coordinator of Northern Iraq.
- 3-4<sup>th</sup> April 2002** Duhok, Kurdistan, **IRAQ**, First Medical conference of the college of medicines. Organized by University of Duhok.
- 5-6<sup>th</sup> Sep 2003** Baghdad, **IRAQ**, A workshop on child protection. Organized by ministry of health/Baghdad.
- 5-6<sup>th</sup> May 2004** Erbil, Kurdistan, **IRAQ**, Second Medical conference conducted at Ministry of health conference hall.
- 16-20<sup>th</sup> Sep 2006** Duhok, Kurdistan-**IRAQ**, International Classification of Diseases 10<sup>th</sup> revision workshop.
- 20-24<sup>th</sup> Aug 2006** Erbid, **JORDAN**, Overview on provision of health services in Jordanian hospitals and getting information on the learning aspects in University of Science and Technology at Erbid
- 11-14<sup>th</sup> Dec 2006** Cairo, **EGYPT**, Intercountry workshop on rapid response for avian and pandemic influenza: training of trainers. Organized by WHO Eastern Mediterranean Region.
- 2-17<sup>th</sup> Sep 2007** Seoul, **KOREA**, Training course on Health Policy and Program Management. Organized by planned population federation of Korea and the Korea international cooperation agency of the Republic of Korea.
- 9-14<sup>th</sup> Jun 2008** Tehran, **IRAN**, Training course on Hospital Infection Control. Organized by Masih Danshveri Hospital in collaboration with WHO.
- 28<sup>th</sup>Jun–2<sup>nd</sup>Jul 2009** Gothenburg, **SWEDEN**, 3<sup>rd</sup> Congress of European Microbiologists - Federation of European Microbiological Societies (FEMS).

- 5-8<sup>th</sup> Jul 2009** Porto, **PORTUGAL**, 30<sup>th</sup> Annual Congress - European Society of Mycobacteriology
- 11-15<sup>th</sup> Nov 2010** Berlin, **GERMANY**, 41 Union world conference on lung health – International Union Against Tuberculosis and Lung Disease
- 14-16 Dec 2010** Diyarbaker, **TURKEY**- Second Mesopotamian Health Days Congress.
- 2-4 Feb 2011** Erbil, Kurdistan, **IRAQ**, International Congress on Reform and Development of the Health Care System in Kurdistan Region-Iraq. Conference Cordinator
- 28-29 Oct 2011** Duhok, Kurdistan, **IRAQ**, Third Mesopotamian Health Days Congress. Conference coordinator
- 19-20<sup>th</sup> Sep 2012** Duhok, Kurdistan, **IRAQ**, the Second Scientific Conference of the Faculty of Medical Sciences, University of Duhok.
- 15-17 May 2014** Tehran, **IRAN**, 5<sup>th</sup> International Tehran Hepatitis Congress.
- 03-06 July 2016** Catania, **ITALY**, 37<sup>th</sup> Annual Congress of the European Society of Mycobacteriology (ESM).
- 26 Oct-11Nov 2016** Milan, **ITALY**, Villa Marelli Institute, Niguarda Hospital. Training course on TB management in addition to training on viral hepatitis. Furthermore, training on Fibroscan machine.
- 26-27 Feb 2017** Babylon, **IRAQ**, Second International Conference for Medical Education, College of Medicine, University of Babylon.
- 28 Feb – 1 Mar 2017** Kufa, **IRAQ**, Medical education and accreditation training, College of Medicine, University of Kufa.
- 18 – 20 Apr 2017** Zakho, Duhok, Kurdistan, **IRAQ**, 2<sup>nd</sup> International Scientific Conference, University of Zakho.
- 04-05 Aug 2017** Duhok, Kurdistan, **IRAQ**, Training Workshop on Integrated System of Medical Education, College of Medicine, UOD in coordination with College of Medicine, University of Kufa.
- 18-22 Sep 2017** Milan, **ITALY**, San Raffaele Turro, Department of Infectious Diseases and Tropical Diseases, IRCCS Ospedale San Raffaele. Clinical traing course in human

immunodeficiency virus disease.

- 03-05 Dec 2017** Amman, **JORDAN** Training course on interferon gamma release assay- plus (IGRA plus) in TB management.
- 17-21 Mar 2018** Baghdad, **IRAQ**, Workshop on management of multi-drug resistant tuberculosis (MDR-TB) cases in Rasheed hotel organized by Ministry of Health, Iraq in collaboration with WHO and IOM.
- 21-24 Nov 2018** Kosice, **SLOVAKIA**, Training for medical education via innovative e-technology (MediTec), Erasmus programme capacity building in the field of higher education.
- 14-18 Jan 2019** Brno, **CZECH REPUBLIC**, Training for medical education via innovative e-technology (MediTec)/MediTec Training, Erasmus programme capacity building in the field of higher education.
- 26-28 June 2019** Msida, **MALTA**, Training for medical education via innovative e- technology (MediTec). Erasmus+ programme capacity building in the field of higher education. University of Malta.
- 8-19 July 2019** Glasgow, **SCOTLAND, UK**, Comprehensive training course titled "Training on Infectious Diseases" as part of Erasmus Plus International Credit Mobility (ICM). The training was conducted in Glasgow health services namely: University Hospital Monklands, Queen Elizabeth Hospital, Gartnavel General Hospital and MRC Center for Virus Research.
- 28 May 2021** Duhok, Kurdistan, Iraq - Awarded by the Governor of Duhok, Dr. Ali Tatar, for excellence in managing COVID-19 patients, in celebration of the 52nd anniversary of the establishment of Duhok Governorate. (RÊÛRESMÊN 52 SALÎYA PARÊZGEHBÛNA DIHOKÊ)
- 8-17 April 2022** Gainesville, Florida, USA. Sister City Program between Duhok, Kurdistan and Gainesville in the main sectors of agriculture, health, and tourism.
- 21-25 July 2022** Antalya, **Turkey**, Speaker in scientific workshop showing the importance of quality treatment in healthcare,

- reflecting Tabuk Pharmaceutical's commitment to strengthen its partnership with leading doctors in Iraq.
- 2-4 May 2023** Erbil, Kurdistan, Iraq. As a speaker and representative of the Faili Anfal's, I share my poignant journey of survival under Saddam Hussein's brutal regime. This International Scientific Conference on the Genocide of the Kurdistan Nation (The Genocide of Faili Kurds) stands as a testament to our resilience and a somber reminder of the atrocities we endured.
- 23 Aug 2023** 9<sup>th</sup> position Excellent Paper Award of 2022 in recognition to paper titled "COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan: A retrospective cohort study"

**Positions and experience:-**

- **October 29, 2024:** Vice President for Scientific Affairs at Nawroz University (on secondment within a private university).
- **February 2024 until now:** Principal Collaborator on the DAAD fact-finding mission (German Program) to enhance infectious disease care infrastructure in the Kurdistan region of Northern Iraq. This project was conducted in partnership with the University of Cologne, Germany and the University of Duhok.
- **October 2023,** Scientific committee, College of Medicine, University of Duhok
- **May 5, 2023 until October 28, 2024:** Teaching professor, College of Medicine, University of Duhok
- **Oct 25, 2022 – May 4, 2023:** Teaching professor, College of Pharmacy.
- **October 2021:** Scientific promotion from assistant Professor to Professor
- **19 March 2020 until now:** Supervisor and treating physician of COVID-19 patients in DGOH healthcare services, Duhok Governorate (Letter No. 1399 Issued on 19/03/2020)
- **February 2017:** Primary treating physician of HIV patients in Duhok Governorate
- **18 Sep 2017 until 24 October 2022:** Dean, College of Pharmacy, University of Duhok.
- **October 2015:** Scientific promotion from lecturer to Assistant Professor of Infectious Diseases.

- **September 2015 until 08 May 2016:** Acting Dean, College of Nursing, University of Duhok.
- **2015- until now:** Infectious Diseases Lecturer, Internal Medicine Department, Medical School, Faculty of Medical Sciences, University of Duhok, Iraqi Kurdistan. Furthermore, Infectiologist at Azadi Teaching Hospital and Tuberculosis and Respiratory Center.
- **2013-2015:** Subspecialty fellow student in Infectious Diseases
- **2011–2013:** Infectious Diseases Lecturer, Internal Medicine Department, Medical School, Faculty of Medical Sciences, University of Duhok, Iraqi Kurdistan. Furthermore, Infectious Diseases doctor at Azadi Teaching Hospital, Infectious Diseases Unit with especial interest in viral hepatitis clinic and antibiotic prescription policy.
- **2011- until 2016:** Editorial board in International Journal of Mycobacteriology
- **2016- until now:** Editorial board in Austin Liver
- **2009-2011:** clinical and research activities of PhD in NRITLD, Tehran, Iran. Contract of work with MRC, NRITLD for 1.5 year.
- **April 2007-Dec 2008:** Deputy Director of Azadi General Teaching Hospital, Duhok City, Kurdistan region-Iraq in addition to the original work (Infectious Diseases).
- **December 2005 – March 2007:** Clinical Microbiologist/Azadi hospital, Duhok City, Kurdistan region-Iraq since (3 days per week).
- **November 2005 - March 2007:** Medical Officer/ DGOH, Duhok City, Kurdistan region-Iraq from (3 days per week).
- **September 2004 – September 2005:** Postgraduate (Full time) student in Nottingham University/UK Clinical Microbiology, a full time one year MSc study in Nottingham University. Two days per week (9:00 am – 5:00 pm); theory lectures, Three working days in PICU (Paediatrics intensive care unit)/QMC (Queen Medical Centre), Nottingham, UK
- **February 2002 – February 2004:** Medical doctor and health & nutrition inspector in ELS (S3) organization (NGO) for a 20 months period (2 working days per week).
- **January 2002 – August 2004:** Director (GP) of Malta public clinic (Afternoon working hours), Duhok City, Kurdistan region- Iraq.
- **January 2002 – August 2004:** Medical doctor (GP) and officer (DGOH) (Morning working hours), Duhok City, Kurdistan region-Iraq.
- **October 2001 – December 2001:** Medical doctor (GP) in rural areas.
- Resident House Officer, Azadi and Emergency hospitals- Duhok City, Kurdistan

region from

**October 1999 – October 2001**; two years rotational internship as a Resident House as follows:

|                         |                           |
|-------------------------|---------------------------|
| General Surgery         | 4 months                  |
| Internal Medicine       | 4 months                  |
| Obstetrics & Gynecology | 3 months                  |
| Pediatrics              | 3 months                  |
| General Casualty        | 4 months                  |
| ENT                     | 1 month                   |
| Ophthalmology           | 1 month                   |
| Orthopedics             | 1 month                   |
| Renal Dialysis          | 1 month                   |
| CCU                     | 2 months                  |
| <b>Total</b>            | <b>24 months - 2 Year</b> |

### **Post-graduate students' supervision:**

Supervising over ten postgraduate students across various degree programs, including Master's, PhD, and Board certification in internal medicine.

### **Publications**

1. Taher S, Abdo J, **Merza M**. The surveillance of spike protein mutations of SARS-COV-2 omicron subvariant isolated from Duhok province, Iraq. Journal of Lifelong DentoMedical Health. 2024 Jun 15;1(1):07-13.
2. Raouf GA, Mohammad FK, **Merza MA**. The Potential Risk of Reduced Serum Cholinesterase Activity in COVID-19 Patients Suffering From Cytokine Storm. Cureus. 2024 May;16(5).
3. Ledesma JR, Ma J, Zhang M, Basting AV, Chu HT, Vongpradith A, Novotney A, LeGrand KE, Xu YY, Dai X, Nicholson SI. Global, regional,

- and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021. *The Lancet Infectious Diseases*. 2024 Jan 1.
4. Taher SM, Abdo JM, **Merza MA**. Phylogenetic, Sequencing, and Mutation Analysis of SARS-CoV-2 Omicron (BA. 1) and Its Subvariants (BA. 1.1, BA. 2) During the Fifth Wave of the COVID-19 Pandemic in the Iraqi Kurdistan Region. *Cureus*. 2023;15(11).
  5. Taha SK, Abd KH, Abdulkareem FN, Saleem ZS, Almukhtar SE, **Merza MA**. Clinico-demographic and microbiological profile of acute pyelonephritis in Azadi Teaching Hospital, Duhok province, Iraqi Kurdistan.
  6. Raouf GA, Mohammad FK, **Merza MA**, Raouf G. Polypharmacy and the In Silico Prediction of Potential Body Proteins Targeted by These Drugs Among Hospitalized COVID-19 Patients With Cytokine Storm. *Cureus*. 2023 Nov 15;15(11).
  7. Wunrow HY, Bender RG, Vongpradith A, Sirota SB, Swetschinski LR, Novotney A, Gray AP, Ikuta KS, Sharara F, Wool EE, Aali A. Global, regional, and national burden of meningitis and its aetiologies, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Neurology*. 2023 Aug 1;22(8):685-711.
  8. Abdulkader Sr MA, **Merza MA**. Immediate and long-term adverse events of COVID-19 vaccines: a one-year follow-up study from the Kurdistan Region of Iraq. *Cureus*. 2023;15(10).
  9. **Merza M**, Mohammed S, Qasim A, Abdulah D. Sero-prevalence and associated risk factors of blood-borne viral infection among healthcare workers of a tertiary referral hospital: a single-center experience. *Health Problems of Civilization*. 2023;17(1).
  10. Rasho FJ, **Merza MA**. The Impact of Blood Group Phenotypes on COVID-19 Severity and Mortality in Duhok Province: a Prospective Cross-sectional Study. *Journal of Contemporary Medical Sciences*. 2023 Mar 1;9(2).
  11. Abdulkareem FN, **Merza MA**, Salih AM, Rekani AI. High Isoniazid Preventive Therapy Completion Rate among Household Contacts of Tuberculosis Patients in Duhok Province. *Journal of Population Therapeutics and Clinical Pharmacology*. 2023 Jun 1;30(12):366-71.
  12. Sulaiman DM, Shaba SS, Almufty HB, Sulaiman AM, **Merza MA**. Screening

- the Drug-Drug Interactions Between Antimicrobials and Other Prescribed Medications Using Google Bard and Lexicomp® Online™ Database. *Cureus*. 2023;15(9).
13. **Merza M**, Abdulah D, Malo D, Haleem D, Atrushi D. Current status of COVID-19 infection and vaccination coverage, and factors associated with infection acquisition and vaccine uptake. *Infect. Dis. Trop. Med.* 2023;9:e1062.
  14. Almufty HB, Hayhat LS, Abdal WG, Hussein DS, **Merza MA**. The Magnitude of Dispensing Unprescribed Antibiotics in Community Pharmacies in Duhok Province; Kurdistan Region of Iraq. *Journal of Contemporary Medical Sciences*. 2023 Mar 1;9(2).
  15. Dhirar K, **Merza M**, Abduljabbar R. Humoral Immunity Response of COVID-19 Vaccine and Adverse Effect Among Solid Cancer Patient: A Prospective Cross-Sectional Study. *Journal of Pharmaceutical Negative Results*. 2023 Feb 6:561-8.
  16. **Merza MA**, Almufty HB, Younis HA, Rasool SO, Mohammed SA. Memory impairment among recovered COVID-19 patients: The prevalence and risk factors, a retrospective cohort study. *Journal of Medical Virology*. 2023 Feb;95(2):e28459.
  17. Hussein H, Salih A, **Merza M**. Prevalence and Outcomes of Diabetes among Covid-19 Patients in Duhok Covid-19 Health Facilities: A Cross-Sectional Study. *Health Problems of Civilization*. 2022 Dec 24;16(1).
  18. Mohammed PA, **Merza MA**. Characterization of COVID-19 hospitalized adult patients, vaccinated vs non-vaccinated in Duhok province. *Journal of Contemporary Medical Sciences*. 2022; 8(6). <https://doi.org/10.22317/jcms.v8i6.1272>
  19. Almufty HB, Mamani MM, Ali AH, **Merza MA**. COVID-19 vaccine breakthrough infection among fully vaccinated healthcare workers in Duhok governorate, Iraqi Kurdistan: A retrospective cohort study. *Journal of Medical Virology*. 2022 Jul 10.
  20. Abdulkader M, **Merza M**. The evaluation of COVID-19 vaccination program in Duhok province, Iraqi Kurdistan: challenges and solutions. *Journal of Research and Health*. 2022 Jun 10;12(4):2-2.
  21. **Merza MA**, Almufty HB. The Omicron variant is striking Iraqi Kurdistan in

- January 2022: Would preventive measures contain the new wave?. *Disaster Medicine and Public Health Preparedness*.:1-5.
22. **Merza MA**, Ahmed BD. Capacity building programs for COVID-19 outbreak in Duhok governorate: A short report. *World Journal of Advanced Research and Review*. 2022.
  23. Zaman BA, Rasool SO, **Merza MA**, Abdulah DM. Hcpidin-to-ferritin ratio: A potential novel index to predict iron overload-liver fibrosis in  $\beta$ -thalassemia major. *Transfusion Clinique et Biologique*. 2022 May 1;29(2):153-60.
  24. Almufty HB, Mohammed SH, Abdullah AM, **Merza MA**. Potential adverse effects of COVID-19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. *Diabetes Metab Syndr*. 2021. <https://doi.org/10.1016/j.dsx.2021.102207>
  25. **Merza MA**, Aswad SM, Sulaiman HM, Abdulah DM, Rasheed WS, and Taib NI. "Clinical and epidemiological characteristics and outcomes of Coronavirus disease-19 patients in a large longitudinal study." *International Journal of Health Sciences* 15, no. 4 (2021): 29-41.
  26. **Merza MA**, Abdulah DM, Mohammed HM, Yones AM. Epidemiological Trends of Coronavirus Disease 2019 in Iraqi Kurdistan. *Disaster Medicine and Public Health Preparedness*. 2021; 19:1-6.
  27. **Merza MA**, Al Mezori AA, Mohammed HM, Abdulah DM. COVID-19 outbreak in Iraqi Kurdistan: The first report characterizing epidemiological, clinical, laboratory, and radiological findings of the disease. *Diabetes Metab Syndr*. 2020; 14(4): 547–554. doi: 10.1016/j.dsx.2020.04.047
  28. **Merza MA**. A 5-year experience characterizing the demographic and clinical profile and directly observed treatment short-course treatment outcome in National Tuberculosis Center of Duhok province, Iraqi Kurdistan. *SAGE Open Med*. 2020; 8: 2050312120921055.
  29. Abdulkareem FN, **Merza MA**, Salih AM. First insight into latent tuberculosis infection among household contacts of tuberculosis patients in Duhok, Iraqi Kurdistan: using tuberculin skin test and QuantiFERON-TB Gold Plus test. *Int J Infect Dis* 2020; 96:97- 104. doi: 10.1016/j.ijid.2020.03.067.
  30. **Merza MA**. Seroprevalence and Risk Factors of Hepatitis B and C Viruses Among Diabetes Mellitus Patients in Duhok Province, Iraqi Kurdistan. *J Family Med Prim Care*2020;9(2):642-646. doi:

10.4103/jfmpe.jfmpe\_1158\_19.

31. **Merza MA**, Taha SK, Ibrahim SM, Abdulrahman MR. Significant Association of Thrombocytopenia with Chronic Active Hepatitis B Virus Infection in a tertiary care hospital of an intermediate prevalence HBV country. *Asian J. Med. Biol. Res.* 2019, 5 (3), 207-211.
32. Almufty HB, Abdulrahman IS, **Merza MA**. Latent Tuberculosis Infection among Healthcare Workers in Duhok Province: From Screening to Prophylactic Treatment. *Tropical Medicine and Infectious Disease.* 2019 Jun; 4(2):85.
33. **Merza MA**, Adham DK, Yaqo RT. Unusual recurrent skin lesions: Bazin's disease. *Int J Community Med Public Health* 2019;6:879-882.
34. **Merza MA**, Savo AS, Jaafer M. Risk of latent tuberculosis infection among diabetic patients in Azadi Teaching Hospital, Duhok province: a case control study. *Asian J. Med. Biol. Res.* 2018, 4 (2), 227-232.
35. **Merza MA**, Yousif BM, Younus MK, Omer BM, Ahmed HI. Characteristics of patients with HBeAg negative chronic hepatitis B virus infection in Duhok, Kurdistan region. *Int J Res Med Sci.* 2018, 6(5): 2615-2620
36. **Merza MA**, Selivany BJ, Aldoski MRN. Prevalence of Hepatitis B and C Viruses among Patients. Who Underwent Dental Interventions in a Dental Care. Units at College of Dentistry, Duhok, Kurdistan. *JICJME* 2017, 3(6): 1-4.
37. **Merza MA**, Merza MA, Savo AS, Barwari ZA, et al. (2017). Hepatitis C Virus Infection and the Risk of Chronic Obstructive Pulmonary Diseases in Azadi Teaching Hospital, Duhok, Kurdistan. *Res Rev Infect Dis* 1(2):21-25.
38. **Merza MA**, Characteristics of Chronic Hepatitis B Virus. Patients Related Liver Cirrhosis in a Tertiary. Care Referral Hospital, Duhok, Iraqi Kurdistan. *J Gastroenterol Pancreatol Liver Disord* 2017. 4:1-5.
39. Mohammed RA, Salih AM, **Mirza MA**, Ismail TH, Allam AA. Prognosis of Liver Disorders in Dna Positive Hbv Patients Based on Fuzzy Soft Sets. *Science Journal of University of Zakho* 2017: 5(1): 112-119.
40. Muter Muhammed, **Merza MA**, Issa HA, Shaikhow SK. Risk Factors and Angiographic Findings in Patients with LBBB Who Underwent Coronary Angiography in Duhok Heart Center. *JMSCR* 2016;4(11):14112-14117.

41. **Merza MA**, Haji SM, Alsharafani AMH, Muhammed SU. Low prevalence of hepatitis B and C among tuberculosis patients in Duhok Province, Kurdistan: Are HBsAg and anti- HCV prerequisite screening parameters in tuberculosis control program? *IJMyco*.2016; 5(3): 313-317
42. Yadegarynia D, **Merza MA**, Sali S, Seghatoleslami ZS. Multiple intracranial tuberculomas in a post-kidney transplant patient. *Saudi J Kidney Dis Transpl*. 2016;27(1):135-8
43. Sali Si, **Merza MA**, Saadat S, Mustafa NH, Queiky F, Yadegarynia D. Seroclearance of Hbsag in Chronic Hepatitis B Virus Patients on Lamivudine Therapy: A 10 Year Experience *Glob J Health Sci*; 2015: 7(6): 101-104.
44. Sali S, Sharafi H, Alavian SH, Alavian SM, Etesam F, Salimi S, **Merza MA**, Keshvari M. Can serum level of HBsAg differentiate HBeAg-negative chronic hepatitis B from inactive carrier state? *Diagn Microbiol Infect Dis*. 2015.
45. **Merza MA**. Risk factors for multi-drug resistant tuberculosis of Afghan immigrants in a tertiary care hospitalized tuberculosis patients in Iran. *IJCR* 2015;7(1):12032-12035.
46. **Merza MA**, Hassan WM, Muhammad AS. Frequency of HBV and HCV among Patients Undergoing Elective Surgery in a Tertiary Care Referral Hospital in Duhok, Iraqi Kurdistan.*JMSCR* 2014;2(4):1810-1815.
47. Velayati AA, **Merza MA**, Frania P. Association of P2X7 gene polymorphisms with chronic hepatitis B virus infection in Duhok, Iraqi Kurdistan. *International Journal of Sciences: Basic and Applied Research (IJSBAR)* 2014;16(2): 131-137.
48. Yadegarynia D, **Merza MA**, Sali Sh, Firuzkuhi AG. A rare case presentation of oral actinomycosis. *IJMyco*; 2013; 2(3): 187-189.
49. Sali Sh, **Merza MA**, Yadegarynia D. Occupational Exposure to Blood Borne Viruses Among Healthcare Workers in a Tertiary Care Referral Hospital in Tehran. *Hepat Mon*. 2013. 13(7): e12201. DOI: 10.5812/hepatmon.12201
50. Abdullah SM, Hussein NR, Salih AM, **Merza MA**, Goreal AA, Odeesh OY, et al. Infection with *Helicobacter pylori* strains carrying babA2 and cagA is associated with an increased risk of peptic ulcer disease development in Iraq. *Arab J Gastroenterol*. 2012 Dec;13(4):166-9. doi: 10.1016/j.ajg.2012.12.001. Epub 2013 Jan 8.
51. Rosales S, Jureen P, Zalutskayae A, Skrahina A, Xu B, Hu Y, Pineda-Garcia

- L, **Merza MA**, et al. Drug resistance-related mutations in multidrug-resistant *Mycobacterium tuberculosis* isolates from diverse geographical regions. 2012;3:124-130.
52. **Merza MA**, Jabrial FK, Hussein NR. Intestinal obstruction secondary to primary ileocecal tuberculosis: A case report. *IJMyco*; 2012; 1(2): 96-98.
53. **Merza MA**, Salih AM. First insight into the genetic diversity of *Mycobacterium tuberculosis* strains from patients in Duhok, Iraq. *IJMyco*; 2012 (1)1: 13-20.
54. Velayati AA, Farnia P, Masjedi MR, Zhavnerko GK, **Merza MA**, Ghanavi J, et al. Sequential adaptation in latent tuberculosis bacilli: observation by atomic force microscopy (AFM). *Int J Clin Exp Med*; 2011;4(3):193-189. Epub 2011 Sep 15.
55. Sheikholslami M, Farnia P, Tabarsi P, **Merza MA**, Pooramiri MV, Mohammadi F, et al. Comparison of polymerase chain reaction single-strand conformation polymorphism with DNA sequencing to detect drug resistance of mycobacterium tuberculosis isolates. *Iranian Journal of Clinical Infectious Diseases* 2011; 6(2): 66-70.
56. **Merza MA**, Farnia P, Tabarsi P, Kazampour M, Masjedi MR, Velayati AA. Anti-tuberculosis drug resistance and associated risk factors in a tertiary level TB center in Iran: a retrospective analysis. *J Infect Dev Ctries* 2011; 5(7):511-519.
57. **Merza MA**, Farnia P, Salih AM, Masjedi MR, Velayati AA. First insight into the drug resistance pattern of *Mycobacterium tuberculosis* in Dohuk, Iraq: using spoligotyping and MIRU-VNTR to characterize multidrug resistant strains. *J Infect Public Health* 2011;4:41-47.
58. Velayati AA, Farnia P, **Merza MA**, Zhavnerko GK, Tabarsi P, Titov LP, et al. New insight into extremely drug-resistant tuberculosis: using atomic force microscopy. *Eur Respir J*; 2010;36(6):1490-1493.
59. Farnia P, Mohammad RM, **Merza MA**, Tabarsi P, Zhavnerko GK, Ibrahim TA, et al. Growth and cell-division in extensive (XDR) and extremely drug resistant (XXDR) tuberculosis strains: transmission and atomic force observation. *Int J Clin Exp Med* 2010;3:308-314.
60. **Merza MA**, Farnia P, Salih AM, Masjedi MR, Velayati AA. The most predominant Spoligopatterns of *Mycobacterium tuberculosis* isolates among

- Iranian, Afghan- Immigrant, Pakistani and Turkish tuberculosis patients: a comparative analysis. *Chemotherapy* 2010;56:248-257.
61. **Merza MA**, Farnia P, Masjedi MR, Ridell M. Anti-tuberculosis drug resistance in Duhok, Iraq. *Int J Tuberc Lung Dis* 2010;14:1213-1214.
  62. Tabarsi P, **Merza MA**, Marjani M. Active pulmonary tuberculosis manifesting with idiopathic thrombocytopenic purpura: a rare presentation. *Braz J Infect Dis* 2010;14:639- 640.
  63. **Merza M**, Masjedi MR. Extensively drug-resistant tuberculosis (XDR) and extremely drug-resistant tuberculosis (XXDR): risk factors and molecular perspectives. *Iranian Journal of Clinical Infectious Diseases* 2010; 5(3):174-188.
  64. Salih AM, **Merza MA**. Risk factors for multidrug resistant tuberculosis: a review. *Duhok Med J* 2010; 4(2):1-7.
  65. Jafarian M, **Aghali-Merza M**, Farnia P, Ahmadi M, Masjedi MR, Velayati AA. Synchronous Comparison of Mycobacterium tuberculosis Epidemiology Strains by "MIRU-VNTR" and "MIRU-VNTR and Spoligotyping" Technique. *Avicenna J Med Biotechnol.* 2010 Jul;2(3):145-52.
  66. **Merza M**, Farnia P, Anoosheh S, Varahram M, Kazampour M, Pajand O et al. The NRAMPI, VDR and TNF-alpha gene polymorphisms in Iranian tuberculosis patients: the study on host susceptibility. *Braz J Infect Dis* 2009; 13:252-256.
  67. Varahram M, Farnia P, Anoosheh S, Kazampour M, **Merza M**, Saeif S, et al. The VDR and TNF- $\alpha$  gene polymorphisms in Iranian tuberculosis patients: The study on host susceptibility. *Iranian Journal of Clinical Infectious Diseases* 2009;4:207-213.

### **Poster presentations (Abstracts) e.g.s**

1. **Merza MA**. Genotyping of *Mycobacterium tuberculosis* isolates in the Dohuk city of Iraq using MIRU-VNTR. 2010. Presented at IUATLD, Berlin, Germany.
2. Sheikholslami M, Farnia P, Seif S, Bayat M, Anoshe S, **Mirza MA**, Masjedi MR, Velayati AA. The relationship between single nucleotide polymorphism of interferon gamma receptor 1 and susceptibility to tuberculosis. 2010. Presented at ERS, Barcelona, Spain.
3. **Merza MA**, Farnia P, Salih AM, Masjedi MR, Velayati AA. The predominant Spoligopatterns of *Mycobacterium tuberculosis* isolates from Iranian, Afghan patients and its comparison to Turkey and Pakistan. 2009. Presented at FEMS, Gothenburg, Sweden.